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Abstract
Background: Chlamydia trachomatis (Ct) is not a disease subject to mandatory reporting in Brazil, and the
prevalence rate of this genital infection varies according to the region in which studies are conducted, as well as by
the detection technique employed. Ct has been associated with persistence of Human papillomavirus (HPV)
infection and the facilitation of cervical carcinoma development. We evaluated the Chlamydia trachomatis infection
and its association with cytology, p16/Ki-67 dual-stained cytology and cervical intraepithelial lesions status in a
screening cohort in Brazil.
Methods: This was a cross-sectional study of 1481 cervical samples from asymptomatic women aged 18 to 64.
Samples were collected for liquid-based cytology and Ct detection by polymerase chain reaction. p16/Ki-67 double
staining was performed on samples with abnormal cytology. Statistical analysis was by chi-square and likelihood-ratio
tests. Odds ratio (OR) and 95% confidence intervals (95% CI) were determined.
Results: The frequency of Ct was 15.6% and its presence was not associated with detection of p16/Ki-67 [OR = 1.
35 (0.5–3.4)]. There was also no association between abnormal cervical cytology and Ct-positivity [OR = 1.21 (0.46–3.2)].
Associations were observed between p16/Ki-67 and high-grade lesions detected by cytology and in biopsies [OR = 3.55
(1.50–8.42) and OR = 19.00 (0.6–7.2), respectively].
Conclusions: The asymptomatic women in our study had a high frequency of Ct infection but this was not associated
with p16/Ki-67 detection in samples with abnormal cytology. The expression of p16/Ki-67 was highest in women with
high-grade CIN (p = 0.003).
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Background
Chlamydia trachomatis (Ct) is not a disease subject to
mandatory reporting in Brazil, and the prevalence rate
of this genital infection varies according to the region in
which studies are conducted, as well as by the detection
technique employed [1–4]. Ct has been associated with
persistence of Human papillomavirus (HPV) infection
and the facilitation of cervical carcinoma development.
It has also been hypothesized that Ct may promote HPV
access and entry in to the basal layer of the epithelium
by inducing chronic inflammation, cervical hypertrophy
and metaplasia. Metaplasia is a preferred HPV target [5].
and these biological effects increase the risk of cervical
cell transformation and the persistence of infection by
oncogenic HPV types. A concomitant Ct and HPV infec-
tion is hypothesized to increase the expression of Ki-67
(a marker for proliferation of the cervical epithelium) by
HPV-generated mitogenic actions and by the anti-
apoptotic activity elicited by both infectious agents [5].
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Ct may also increase protein expression of oncogenic
HPV16 in low-grade lesions [5].
Cervical cancer screening via cytology may reduce
mortality by up to 50% under appropriate conditions
and when solid population coverage is implemented;
however, the sensitivity of cytology to detect CIN or in-
vasive cancer may be <60% [6].
An increased understanding of how HPV contributes
to cervical cell neoplastic transformation led to the rou-
tine use of biomarkers, such as p16, to identify HPV-
mediated transformation. Studies have suggested that
analysis for the p16 biomarker by cytology and histology
in cervical lesions may have clinical utility by optimizing
the efficiency of cytological tests [7]. Such findings have
ensured greater efficiency in the early detection of cer-
vical cancer. However, since some normal cervical cells
may express p16, it is necessary to conduct additional
morphologic evaluations. A recently developed p16 and
Ki-67 detection kit enables the recognition of abnormal
cells based on the double staining of both markers in
the same cell, thereby possibly reducing the need for
morphologic interpretation [7].
Recent publications claims that p16/Ki-67 detect
oncogenic molecular changes induced by a persistent
HPV infection in the cell through detection of concord-
ant expression of the tumors suppressor protein p16
(also cyclin-dependent kinase inhibitor 2A) and the pro-
liferation marker Ki-67 in the same cell, which are mu-
tually exclusive in cells with a normal cell cycle. Since
the latter cells are consistently cell cycle arrested, the
combination of antibodies detecting p16INK4a and the
cell cycle progression marker Ki-67 in one cell allows for
the unequivocal identification of truly HPV-transformed
cervical cells [8, 9].
The present study was conducted to analyze Chlamydia
trachomatis infection and its status with cytology, p16/
Ki-67 dual-stained cytology and CIN status in a screening
cohort in Brazil.
Methods
This was a cross-sectional study of 1481 cervical samples
preserved in liquid media, collected from asymptomatic
women aged 18 to 64 and enrolled in a cervical cancer
screening project in one clinical center (Leonor Mendes
de Barros Hospital) in Sao Paulo, Brazil. Pregnant or
hysterectomized women or women being treated for cer-
vical neoplasia were excluded from the study. All women
included in the study filled out a questionnaire on risk
factors for cervical cancer. Cervical samples were col-
lected at the ectocervix/endocervical junction with a
Rover’s Cervex-Brush and the material was placed in the
liquid preservative medium (Fig. 1).
Cytology slides preparation
The entire brush head was introduced into the tube
containing the BD SurePath™ liquid (BD Diagnostics –
TriPath, Burlington, NC, USA), and sent to laboratory.
The slides were prepared according to the manu-
facturer’s instructions, using BD PrepMate™ and BD
PrepStain™. All liquid-based preparations were per-
formed with a semi-automated methodology, accor-
ding to the manufacturer’s instructions and manually
analyzed.
Cytological changes were classified according to the
2014 Bethesda System [10] A colposcopy examination
was requested for women with cytological abnormalities
equal to or worse than Atypical Squamous Cells of
Undetermined Significance (ASCUS).
Chlamydia trachomatis detection
One thousand four hundred eighty one samples were
collected for Ct detection in the BD cytology residual
Fig. 1 Description of Biopsies According to Presence of Chlamydia trachomatis. Flowchart for the tests performed. CIN cervical intraepithelial
neoplasia, Ct Chlamydia trachomatis
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medium with the BD ProbeTec Amplified DNA Test,
according to the manufacturer’s instructions.
Immunocytochemistry of p16/Ki-67 dual-staining
The CINtec PLUS p16/Ki-67 dual-staining analysis
was conducted in cytology results equal to or worse
than ASCUS.
Immunostaining was performed according to the
manufacturer’s instructions (Ventana, currently Roche
Diagnostics GmbH, Mannheim, Germany).
The slides were analyzed searching for the presence of
cervical epithelial cytoplasmic brown color and a red nu-
clear color, indicating concurrent expression of p16 and
Ki-67. The presence of one or more cervical epithelial
cells with both brown and red color was interpreted as a
positive test result. The analyses were made by one of
the authors (ALF).
Statistics
Sample size for this study was based on the study of
Santos et al. (2002), which detected a Ct prevalence of
20.7% in women aged 14 to 63. To obtain a similar fre-
quency, with 95% CI and 2% error, the present study
would have to include 1576 women. However, due to
reading failures and material losses, 1481 women were
analyzed, thereby attributing an error of 2.07% to the
study.
Statistical analysis was conducted based on chi-
squared or likelihood-ratio tests. Odds ratio (OR) and
the respective 95% confidence intervals (95% CI) were
estimated.
Results
Characteristics of the study population
The ages of the women enrolled for cervical cancer
screening ranged from 18 to 64 years, with a mean of
40 years (SD = 11.2). Most women self-identified as
White (58%), 33% were Afro-American while the
remaining 9% were mixed race. The majority of subjects
(57%) had a stable partner. The mean age at first sexual
intercourse was 18 years (SD = 3.9). The number of life-
time sexual partners ranged from 1 to 30, with a mean
of 3 partners (SD = 2.5).
Among the 1,481 women, 772 reported to have had at
least one prior Pap test examination. Among of the 1351
women who answered the question regarding previous
sexually transmitted disease (STD), 87% reported not to
have had any prior STD. In relation to smoking, 64% of
the women reported to never have smoked, and 17% of
the women stopped smoking in the past 12 months.
Frequency of Ct and association with p16/Ki-67
The Ct frequency was of 15.9%. No association was found
between Ct and p16/Ki-67 positivity in women with
abnormal cytology (Table 1). Only age (Table 2) and the
number of lifetime sexual partners (Table 3) showed an
association with detection of Ct (Tables 1 and 2).
In particular women between 35 and 45 years old had
a higher rate of Ct positivity when compared to women
in other age groups. Women with over 10 lifetime part-
ners had the highest rate of being positive for Ct (p
= 0.015 OR = 4.14) (Tables 3, 4 and 5).
Among the histological results, women diagnosed with
CIN1 had a higher frequency of Ct compared to women
with other cytological findings, but the difference was
not statistically significant (p = 0.112) (Table 6).
Regarding the cytological findings, there was an asso-
ciation between p16/Ki-67 positivity and detection of
high-grade lesions (OR = 3.55), confirmed in women
with CIN 2/3 who were highly positive for p16/Ki67
(Tables 7 and 8).
Discussion
Prior studies have investigated the role of microorgan-
isms like Ct that cause a chronic inflammation as a po-
tential risk factor in the transmission and persistence of
HPV, as well as contributing to the progression of cer-
vical carcinogenesis [11, 12]. Our study population had a
15.6% frequency of Ct infection, as assessed by analysis
of the liquid preservative media utilized for cervical
cancer screening. However, we did not detect an associ-
ation between p16/Ki-67 expression and Ct in women
with CIN.
In Brazil, four studies conducted in different states,
one in Goiás, two in Paraná and one in Rio Grande do
Norte showed a Ct prevalence of 10.9, 10.7, 12.7 and
10.9%, respectively, also compatible with results in the
present study. A study conducted in the city of Manaus
had a higher prevalence of 20.7%, and may be explained
by regional or socioeconomic reasons [4, 13–15].
Ct is not an infection subjected to mandatory reporting
in Brazil. Additionally, there are no specific programs im-
plemented by the Ministry of Health to encourage screen-
ing for this infection. Because it is asymptomatic in most
women, it is likely to be under-diagnosed. As such, its true
prevalence in this country remains ambiguous. Asymp-
tomatic untested women are obviously not treated. This
may account for the high number of positive women in
our study. The Ct prevalence estimates must be
Table 1 Association of Chlamydia trachomatis with p16/Ki-67
Variable Chlamydia OR (95% CI) Total P
Negative Positive
n % n %
p16/Ki67
Negative 140 84.3 26 15.7 1 166 0.529
Positive 28 80.0 7 20.0 1.35 (0.5–3.4) 35
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interpreted within the context of national and cultural
differences, of sexual behavior and the health system.
Brazil is a very large country whose population has
different cultural and socioeconomic development
levels, which most likely explains the reported regional
differences [16–18].
Age was the only demographic variable in this study
that was associated with Ct infection. Women aged 35
to 45 years had the highest likelihood of being Ct posi-
tive. This observation differs from studies conducted in
the United States, where the highest prevalence was
among women aged 15 to 24 years. In the United States
Table 2 Frequency of Chlamydia trachomatis according to demographic variables
Variable Chlamydia trachomatis OR (95% CI) Total p
Negative Positive
n % n %
Age Group
≤ 25 125 88.7 16 11.3 1 141 0.040
26–35 295 84.5 54 15.5 1.43 (0.8–2.6) 349
36–45 352 80.2 87 19.8 1.93 (1.1–3.4) 439
46–55 352 86.3 56 13.7 1.24 (0.7–2.2) 408
> 55 126 87.5 18 12.7 1.12 (0.5–2.3) 144
Schooling (Years)
< 8 392 82.9 81 17.1 1 473 0.156
8–11 634 86.4 100 13.6 0.76 (0.6–1.0) 734
> 11 182 82.4 39 17.6 1.04 (0.7–1.6) 221
Marital Status
Single 530 85.8 88 14.2 1 618 0.211
Living with partner 696 83.4 139 16.6 1.20 (0.9–1.6) 835
Smoking
Never 793 85.7 132 14.3 1 925 0.128
Currently 234 81.0 55 19.0 1.41 (1.0–2.0) 289
Previously 202 83.1 41 16.9 1.22 (0.8–1.8) 243
Table 3 Frequency of Chlamydia trachomatis according to
sexual and obstetric history
Age at sexual debut (years)
< 15 299 84.0 57 16.0 1 356 0.875
16–19 622 84.6 113 15.4 0.95 (0.7–1.3) 735
> 19 298 85.4 51 14.6 0.90 (0.6–1.3) 349
Number of Lifetime Partners
1–4 1022 85.3 176 14.7 1 1198 0.015
5–10 195 82.3 42 17.7 1.25 (0.9–1.8) 237
> 10 12 60.0 8 40.0 3.87 (1.56–9.61) 20
Number of Partners in the Past Year
0–1 1160 84.7 209 15.3 1 1369 0.709
2–4 75 81.5 17 18.5 1.26 (0.7–2.2) 92
> 4 5 83.3 1 16.7 1.11 (0.1–9.5) 6
Parity
0 230 85.2 40 14.8 1 270 0.804
1–2 543 85.0 96 15.0 1.02 (0.7–1.5) 639
> 2 443 83.7 86 16.3 1.12 (0.7–1.7) 529
Prior STD
No 999 85.5 170 14.5 1 1169 0.083
Yes 130 80.2 32 19.8 1.45 (0.9–2.2) 162
Table 4 Result of the multiple logistic regression model to
explain chlamydia positivity
Variable OR IC (95%) p
Age group (years)
≤ 25 1.00
> 25 e ≤ 35 1.50 0.81–2.77 0.195
> 35 e ≤ 45 2.01 1.12–3.63 0.020
> 45 e ≤ 55 1.35 0.73–2.47 0.339
> 55 1.26 0.61–2.63 0.532
Number of partners in life
1–4 1.00
5–10 1.20 0.83–1.75 0.332
> 10 4.14 1.66–10.36 0.002
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screening programs for Ct are available for women aged
25 years or younger, and for women at risk for this infec-
tion. Increased testing and treatment may explain the
overall lower prevalence, as well as the lower rate found
among women aged 25 years and older in the United
States as compared to Brazil [12].
When assessing other demographic factors, such as
years of schooling, marital status and smoking, there
was no positive association with Ct presence, similar to
what has been reported in other national studies [13].
The analysis of sexual and obstetric history reveals that
only the number of lifetime partners was associated with
being positive for Ct. Women with more than 10 part-
ners had a four fold higher rate of positivity than did
women with 1–4 partners. This is explained by the fact
that Ct is a sexually transmitted disease, and infection is
associated with high-risk sexual behavior. This association
was also demonstrated in a prior Brazilian study [13].
Because it is an infection in which 90% of infected
women are asymptomatic but, nevertheless, can have
serious consequences for both reproductive and fetal
health, Ct has been considered the non-viral STD with
the highest burden for public health. Several lines of evi-
dence suggest that screening for Ct is cost effective when
its prevalence is above 3%. The few Brazilian studies
conducted until now clearly justify the implementation of
systematic screening of women for this infection [18].
We did not observe an association between abnormal
cervical cytology and the presence of Ct. An analysis of
women with abnormal cytological results revealed a
higher prevalence of Ct infection in women with atypical
lesions (ASCUS), followed by low-grade lesions (LSIL),
in which almost 20% were Ct positive. These observed
rates were similar to other Brazilian studies with women
in the same age group [14].
In women who underwent a colposcopy examination a
greater prevalence of Ct positivity was found in women
with CIN1. However, the lack of statistical significance
may be due to the low number of biopsies conducted
after the cytology results. No prior Brazilian studies have
assessed this association.
Our study was limited by the lack of HPV testing, due
to the limited amount of residual material available. It is
necessary, however, to take into consideration the “sta-
tus” of HPV infection and the natural history of cervical
cancer when determining the role of Ct as a co-factor in
CIN or invasive cancer. HPV infection is a highly preva-
lent sexually transmitted viral infection, whereas Ct is
the most commonly sexually transmitted bacterial infec-
tion, and co-infections with both microorganisms are
quite common. No association was found in this study
between Ct infection and cytology and positive biopsies
for CIN, presumed positive for HPV. These results dif-
fer from other studies that found a positive association
between HPV and Ct detected by serology [19, 20],.
Table 5 Association between Pap smears and Chlamydia trachomatis infection
Variable Chlamydia trachomatis OR (95% CI) Total P
Negative Positive
n % n %
Cytology
Normal/Inflammatory 1038 84.8% 186 15.2 1 1224 0.935
ASCUS 45 80.4 11 19.6 1.36 (0.7–2.7) 56
LSIL 134 83.8 26 16.2 1.08 (0.7–1.7) 160
HSIL 23 82.1 5 17.9 1.21 (0.46–3.2) 28
AGC 6 85.7 1 14.3 0.93 (0.1–7.8) 7
SCC 1 100.0 0 0 #
Table 6 Association between biopsies and Chlamydia trachomatis
infection
Variable Chlamydia trachomatis OR (95% CI) Total P
Negative Positive
n % n %
Histology
Normal 86 79.6% 22 20.4 1 108 0.194
Cervicitis 30 93.8 2 6.2 0.26 (0.06–1.18) 32
CIN 1 21 77.8 6 22.2 1.12 (0.40–3.1) 27
CIN2/3 10 76.9 3 23.1 1.17 (0.3–4.63) 13
CIN 1 cervical intraepithelial neoplasia 1
CIN2/3 cervical intraepithelial neoplasia 2 and 3
Table 7 Association of p16/Ki-67 expression with Low-grade
and High-Grade Cytological Diagnosis
Variable Cytology OR (95% CI) Total P
ASCUS/LSIL HSIL
n % n %
P16/ki67
Negative 141 88.1 19 11.9 1.00 160 0.003
Positive 23 67.6 11 32.4 3.55 (1.50–8.42) 34
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However it was similar to other studies using the
same methodology that did not find any association
between Ct DNA detection and subsequent risk of
CIN2/3 [21, 22].
This study utilized p16/Ki-67 expression as a marker
of transforming HPV infections. The study was designed
to explore the possible association between a Ct infec-
tion and consequences of a persistent HPV infection by
the use of p16/Ki-67, instead of testing for HPV DNA.
In most cases, HPV DNA is unable to distinguish between
persistent and transient infection. We conclude that there
is no association between Ct and p16/Ki-67 positivity in
women with abnormal cytology [22].
Most women with cytological findings were negative
for p16/Ki-67 expression. However, approximately one
fourth of the abnormal cytological results were positive
for p16/Ki-67 double staining, a finding compatible with
publications demonstrating that women with p16/Ki-67
positivity were also the women infected with HPV.
Women with HSIL had a higher positivity prevalence
(37%) than did women with LSIL. p16/Ki-67 positivity is
therefore associated with a threefold higher prevalence
in women with a high-grade lesion. These results were
comparable to a recent study assessing the use of p16/
Ki-67 in a sample from women referred for colposcopy
and finding that this marker indeed had a higher positivity
in women with high-grade lesions [23, 24].
Evaluation of the association of p16/Ki-67 expres-
sion with histopathological results also revealed a
higher rate of p16/Ki-67 positivity in women with
CIN2 or more advanced lesions. p16/Ki-67 positivity
increased with the seriousness of the lesion. When the
biopsy result revealed chronic cervicitis, approxi-
mately 20% of the cases were positive; positivity was
higher with CIN1 (25%) and, in women with CIN2 or
more advanced lesions, almost 70% of the cytological
preparations were positive for the double stain. The
results are consistent with other studies in which p16/
Ki-67 activity in a colposcopy population had similar
associations [24].
A possible relationship between Ct and either cyto-
logical or histopathological alterations characteristic of
HPV infection remains to be clarified. An association be-
tween Ct and a persistent HPV infection may occur pref-
erentially in high-risk women, while a Ct infection may be
associated with the clearance of an HPV infection in
women who develop an intense inflammatory response to
Ct. The identification of women in whom a concurrent Ct
infection may be beneficial or detrimental to HPV persist-
ence and progression remains to be clarified [21, 25, 26].
Conclusion
Ct infection in our study population had a frequency of
15.6% and was associated with age and number of lifetime
sexual partners. It was not associated with p16/Ki-67 ex-
pression in women with CIN. A possible relationship
between Ct and either cytological or histopathological al-
terations leading to development or persistence of HPV
infection remains to be clarified.
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